RCMNY
NKTR icon

Rubric Capital Management (New York)’s Nektar Therapeutics NKTR Stock Holding History

Rubric Capital Management (New York)’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-66,456
Closed -$23.9M – 57
2017
Q3 		$23.9M Buy
+66,456
New +$20.8M 2.17% 11

Other funds holding NKTR

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Rubric Capital Management (New York)'s NKTR Position: Q4 2017 in Review

Rubric Capital Management (New York) sold out of Nektar Therapeutics (NKTR) in Q4 2017, closing a stake of 66,456 shares — an estimated $23.9M sold.

Rubric Capital Management (New York) first reported a position in NKTR in Q3 2017 and held it in 1 quarter. The position peaked at $23.9M in Q3 2017. 265 funds tracked by Wall St. Rank hold NKTR as of Q4 2017.

  • Rubric Capital Management (New York) reported no remaining Nektar Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 66,456 Nektar Therapeutics shares in Q4 2017, an estimated $23.9M.
  • Rubric Capital Management (New York) first reported a position in Nektar Therapeutics in Q3 2017 and held it in 1 quarter.
  • Rubric Capital Management (New York)'s Nektar Therapeutics position peaked at $23.9M in Q3 2017.
  • 265 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2017.

Based on Rubric Capital Management (New York)'s 13F filing for Q4 2017, filed 14 Feb 2018.